Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721723 | 0.79 | ALDH1A1 (0.47) | ALDH1A1CYP1A2EDNRBEDNRA | |
| SCHEMBL1721952 | 0.75 | TRPM5 (0.44) | ALDH1A1 | |
| SCHEMBL3031190 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CYP1A2MEN1LMNAHPGD | |
| SCHEMBL3027196 | 0.71 | MEN1 (0.37) | ALDH1A1MEN1LMNAHPGDKMT2A | |
| SCHEMBL4250760 | 0.69 | ALDH1A1 (0.45) | ALDH1A1MEN1ALOX15KMT2ASMN1; SMN2 | |
| SCHEMBL9742808 | 0.69 | BCL2L1 (0.39) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL9465746 | 0.68 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL8065941 | 0.68 | ALDH1A1 (0.44) | ALDH1A1EDNRBEDNRAHPGD | |
| SCHEMBL19839756 | 0.66 | GID4 (0.44) | ALDH1A1CYP1A2 | |
| SCHEMBL3031059 | 0.64 | RBP4 (0.42) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| EP-2406217-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103001-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2010-09-16 | — | — | WO | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | ALDH1A1 566/4885HTR2A 10/4885HTR2C 2/4885 |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR3C, TPH2 | ALDH1A1 448/4885HTR2A 16/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.